Drug Profile
HPV16 RG1 VLP
Alternative Names: HPV16 RG1-VLP; human papilloma virus vaccine; RGVaxLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator PathoVax
- Class Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in USA (Parenteral)
- 29 Mar 2023 US FDA approves IND application for HPV16 RG1 VLP in Human-papillomavirus-infections
- 28 Mar 2023 PathoVax plans a phase I trial for Human-papillomavirus-infections (Prevention) in the US and Australia